ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) is set to issue its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.16 per share for the quarter. ACADIA Pharmaceuticals has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s conference call can do so using this link.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.06. The business had revenue of $205.83 million for the quarter, compared to analysts’ expectations of $208.31 million. ACADIA Pharmaceuticals had a negative return on equity of 0.41% and a negative net margin of 0.21%. The firm’s revenue was up 73.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) earnings per share. On average, analysts expect ACADIA Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
ACADIA Pharmaceuticals Stock Down 1.7 %
ACAD traded down $0.32 during trading on Tuesday, reaching $18.43. The stock had a trading volume of 400,369 shares, compared to its average volume of 1,755,232. ACADIA Pharmaceuticals has a one year low of $14.55 and a one year high of $32.59. The business has a 50-day moving average of $16.20 and a 200-day moving average of $19.42.
Insiders Place Their Bets
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on ACAD shares. Morgan Stanley reduced their price objective on ACADIA Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, July 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, May 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, June 25th. Citigroup reduced their price objective on ACADIA Pharmaceuticals from $30.19 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Finally, Oppenheimer reaffirmed a “market perform” rating and set a $19.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, May 6th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.59.
Read Our Latest Report on ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Further Reading
- Five stocks we like better than ACADIA Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Financial Services Stocks Investing
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.